Adjuvant Tislelizumab Plus Lenvatinib for Patients at High-risk of HCC Recurrence After Curative Resection or Ablation

NCT05910970 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

200

Enrollment

OTHER

Sponsor class

Conditions

Hepatocellular Carcinoma
Recurrence
Immune Checkpoint Inhibitor

Interventions

DRUG: Adjuvant tislelizumab plus lenvatinib
DRUG: Adjuvant tislelizumab

Sponsor

Guangxi Medical University